Cargando…

Assay establishment and validation of a high-throughput organoid-based drug screening platform

BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features o...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaomeng, Fu, Guoxiang, Zhang, Long, Guan, Ruoyu, Tang, Peiyuan, Zhang, Jialing, Rao, Xinxin, Chen, Shengzhi, Xu, Xiaoya, Zhou, Yi, Deng, Yun, Lv, Tao, He, Xingfeng, Mo, Shaobo, Mu, Peiyuan, Gao, Jianjun, Hua, Guoqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137096/
https://www.ncbi.nlm.nih.gov/pubmed/35619149
http://dx.doi.org/10.1186/s13287-022-02902-3
_version_ 1784714306013626368
author Li, Xiaomeng
Fu, Guoxiang
Zhang, Long
Guan, Ruoyu
Tang, Peiyuan
Zhang, Jialing
Rao, Xinxin
Chen, Shengzhi
Xu, Xiaoya
Zhou, Yi
Deng, Yun
Lv, Tao
He, Xingfeng
Mo, Shaobo
Mu, Peiyuan
Gao, Jianjun
Hua, Guoqiang
author_facet Li, Xiaomeng
Fu, Guoxiang
Zhang, Long
Guan, Ruoyu
Tang, Peiyuan
Zhang, Jialing
Rao, Xinxin
Chen, Shengzhi
Xu, Xiaoya
Zhou, Yi
Deng, Yun
Lv, Tao
He, Xingfeng
Mo, Shaobo
Mu, Peiyuan
Gao, Jianjun
Hua, Guoqiang
author_sort Li, Xiaomeng
collection PubMed
description BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features of corresponding tissues, it makes it incommodious for imaging organoids in two-dimensional and identifying surviving organoids from surrounding dead cells after organoids being treated by irradiation or chemotherapy. Therefore, significant work remains to establish high-quality controls to standardize organoid analyses and make organoid models more reproducible. METHODS: In this study, the Z-stack imaging technique was used for the imaging of three-dimensional organoids to gather all the organoids’ maximum cross sections in one imaging. The combination of live cell staining fluorescent dye Calcein-AM and ImageJ assessment was used to analyze the survival of organoids treated by irradiation or chemotherapy. RESULTS: We have established a novel quantitative high-throughput imaging assay that harnesses the scalability of organoid cultures. Using this assay, we can capture organoid growth over time, measure multiple whole-well organoid readouts, and show the different responses to drug treatments. CONCLUSIONS: In summary, combining the Z-stack imaging technique and fluorescent labeling methods, we established an assay for the imaging and analysis of three-dimensional organoids. Our data demonstrated the feasibility of using organoid-based platforms for high-throughput drug screening assays. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-02902-3.
format Online
Article
Text
id pubmed-9137096
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91370962022-05-28 Assay establishment and validation of a high-throughput organoid-based drug screening platform Li, Xiaomeng Fu, Guoxiang Zhang, Long Guan, Ruoyu Tang, Peiyuan Zhang, Jialing Rao, Xinxin Chen, Shengzhi Xu, Xiaoya Zhou, Yi Deng, Yun Lv, Tao He, Xingfeng Mo, Shaobo Mu, Peiyuan Gao, Jianjun Hua, Guoqiang Stem Cell Res Ther Research BACKGROUND: Organoids are three-dimensional structures that closely recapitulate tissue architecture and cellular composition, thereby holding great promise for organoid-based drug screening. Although growing in three-dimensional provides the possibility for organoids to recapitulate main features of corresponding tissues, it makes it incommodious for imaging organoids in two-dimensional and identifying surviving organoids from surrounding dead cells after organoids being treated by irradiation or chemotherapy. Therefore, significant work remains to establish high-quality controls to standardize organoid analyses and make organoid models more reproducible. METHODS: In this study, the Z-stack imaging technique was used for the imaging of three-dimensional organoids to gather all the organoids’ maximum cross sections in one imaging. The combination of live cell staining fluorescent dye Calcein-AM and ImageJ assessment was used to analyze the survival of organoids treated by irradiation or chemotherapy. RESULTS: We have established a novel quantitative high-throughput imaging assay that harnesses the scalability of organoid cultures. Using this assay, we can capture organoid growth over time, measure multiple whole-well organoid readouts, and show the different responses to drug treatments. CONCLUSIONS: In summary, combining the Z-stack imaging technique and fluorescent labeling methods, we established an assay for the imaging and analysis of three-dimensional organoids. Our data demonstrated the feasibility of using organoid-based platforms for high-throughput drug screening assays. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13287-022-02902-3. BioMed Central 2022-05-26 /pmc/articles/PMC9137096/ /pubmed/35619149 http://dx.doi.org/10.1186/s13287-022-02902-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Li, Xiaomeng
Fu, Guoxiang
Zhang, Long
Guan, Ruoyu
Tang, Peiyuan
Zhang, Jialing
Rao, Xinxin
Chen, Shengzhi
Xu, Xiaoya
Zhou, Yi
Deng, Yun
Lv, Tao
He, Xingfeng
Mo, Shaobo
Mu, Peiyuan
Gao, Jianjun
Hua, Guoqiang
Assay establishment and validation of a high-throughput organoid-based drug screening platform
title Assay establishment and validation of a high-throughput organoid-based drug screening platform
title_full Assay establishment and validation of a high-throughput organoid-based drug screening platform
title_fullStr Assay establishment and validation of a high-throughput organoid-based drug screening platform
title_full_unstemmed Assay establishment and validation of a high-throughput organoid-based drug screening platform
title_short Assay establishment and validation of a high-throughput organoid-based drug screening platform
title_sort assay establishment and validation of a high-throughput organoid-based drug screening platform
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9137096/
https://www.ncbi.nlm.nih.gov/pubmed/35619149
http://dx.doi.org/10.1186/s13287-022-02902-3
work_keys_str_mv AT lixiaomeng assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT fuguoxiang assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT zhanglong assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT guanruoyu assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT tangpeiyuan assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT zhangjialing assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT raoxinxin assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT chenshengzhi assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT xuxiaoya assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT zhouyi assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT dengyun assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT lvtao assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT hexingfeng assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT moshaobo assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT mupeiyuan assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT gaojianjun assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform
AT huaguoqiang assayestablishmentandvalidationofahighthroughputorganoidbaseddrugscreeningplatform